Short Interest in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Drops By 16.9%

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) was the target of a significant decline in short interest in March. As of March 15th, there was short interest totalling 70,200 shares, a decline of 16.9% from the February 28th total of 84,500 shares. Currently, 2.6% of the shares of the stock are short sold. Based on an average trading volume of 415,800 shares, the short-interest ratio is currently 0.2 days.

Institutional Trading of Theriva Biologics

A hedge fund recently bought a new stake in Theriva Biologics stock. Anson Funds Management LP bought a new stake in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned 6.13% of Theriva Biologics at the end of the most recent reporting period. Institutional investors and hedge funds own 6.17% of the company’s stock.

Theriva Biologics Stock Up 5.4 %

Shares of NYSEAMERICAN:TOVX traded up $0.06 during trading on Wednesday, reaching $1.18. The company’s stock had a trading volume of 18,775 shares, compared to its average volume of 994,917. The company’s 50 day moving average price is $1.37. Theriva Biologics has a 12 month low of $1.03 and a 12 month high of $12.28. The stock has a market cap of $3.28 million, a PE ratio of -0.04 and a beta of 1.22.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.